OCX vs. ACHL, DRRX, TKNO, VNRX, ABIO, ICCC, AWH, CDIO, TRIB, and BMRA
Should you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include Achilles Therapeutics (ACHL), DURECT (DRRX), Alpha Teknova (TKNO), VolitionRx (VNRX), ARCA biopharma (ABIO), ImmuCell (ICCC), Aspira Women's Health (AWH), Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), and Biomerica (BMRA). These companies are all part of the "medical" sector.
Achilles Therapeutics (NASDAQ:ACHL) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership and community ranking.
In the previous week, Achilles Therapeutics and Achilles Therapeutics both had 3 articles in the media. OncoCyte's average media sentiment score of 1.44 beat Achilles Therapeutics' score of 0.63 indicating that Achilles Therapeutics is being referred to more favorably in the media.
Achilles Therapeutics has a net margin of 0.00% compared to Achilles Therapeutics' net margin of -2,905.14%. OncoCyte's return on equity of -42.95% beat Achilles Therapeutics' return on equity.
Achilles Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 334.78%. OncoCyte has a consensus target price of $4.06, suggesting a potential upside of 48.27%. Given OncoCyte's higher possible upside, research analysts plainly believe Achilles Therapeutics is more favorable than OncoCyte.
Achilles Therapeutics received 11 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 54.84% of users gave Achilles Therapeutics an outperform vote while only 8.96% of users gave OncoCyte an outperform vote.
OncoCyte has higher revenue and earnings than Achilles Therapeutics.
Achilles Therapeutics has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, OncoCyte has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.
56.4% of Achilles Therapeutics shares are owned by institutional investors. Comparatively, 55.3% of OncoCyte shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by insiders. Comparatively, 1.9% of OncoCyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Achilles Therapeutics beats OncoCyte on 10 of the 14 factors compared between the two stocks.
Get OncoCyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OncoCyte Competitors List
Related Companies and Tools
